Dr. Yan Wang
Claim this profileXiamen Cardiovascular Hospital Xiamen University
Studies Lung Cancer
Studies Non-Small Cell Lung Cancer
16 reported clinical trials
33 drugs studied
Area of expertise
1Lung Cancer
Stage IV
EGFR positive
Stage III
2Non-Small Cell Lung Cancer
EGFR positive
Stage IV
Stage III
Affiliated Hospitals
Clinical Trials Yan Wang is currently running
Apixaban vs Aspirin
for Stroke Prevention in Atrial Fibrillation After Brain Bleed
Primary Aim: To determine if apixaban is superior to aspirin for prevention of the composite outcome of any stroke (hemorrhagic or ischemic) or death from any cause in patients with recent ICH and atrial fibrillation (AF). Secondary Aim: To determine if apixaban, compared with aspirin, results in better functional outcomes as measured by the modified Rankin Scale.
Recruiting1 award Phase 36 criteria
IMP4297 + Temozolomide
for Small Cell Lung Cancer
This is an open-label, multi-center, dose-escalation and dose-expansion phase I study to evaluate the safety, tolerability, PK characteristics and anti-tumor activity of PARP inhibitor IMP4297 and temozolomide combination therapy in patients with advanced solid tumors and with ES-SCLC who develops disease progression after 1L platinum-based regimen.
Recruiting1 award Phase 1 & 210 criteria
More about Yan Wang
Clinical Trial Related4 years of experience running clinical trials · Led 16 trials as a Principal Investigator · 6 Active Clinical TrialsTreatments Yan Wang has experience with
- Aspirin
- Ticagrelor
- Clopidogrel
- Genetic Testing
- Hemo Jirui Intracranial Thrombus Aspiration Catheter System
- Solitaire FR
Breakdown of trials Yan Wang has run
Lung Cancer
- Phase Ib/II Study of SHR-8068 Injection in the Treatment of Advanced Non-small Cell Lung Cancer
- TAK-788 vs Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer
- A Trial of Camrelizumab Combined With Famitinib Malate in Treatment Naïve Subjects With PD-L1-Positive Recurrent or Metastatic Non-Small Cell Lung Cancer
Non-Small Cell Lung Cancer
- Phase Ib/II Study of SHR-8068 Injection in the Treatment of Advanced Non-small Cell Lung Cancer
- TAK-788 vs Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer
- A Trial of Camrelizumab Combined With Famitinib Malate in Treatment Naïve Subjects With PD-L1-Positive Recurrent or Metastatic Non-Small Cell Lung Cancer
Stroke
Solid Tumors
Myocardial Infarction
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Yan Wang specialize in?
Yan Wang focuses on Lung Cancer and Non-Small Cell Lung Cancer. In particular, much of their work with Lung Cancer has involved Stage IV patients, or patients who are EGFR positive.
Is Yan Wang currently recruiting for clinical trials?
Yes, Yan Wang is currently recruiting for 3 clinical trials in Xiamen Fujian. If you're interested in participating, you should apply.
Are there any treatments that Yan Wang has studied deeply?
Yes, Yan Wang has studied treatments such as Aspirin, Ticagrelor, Clopidogrel.
What is the best way to schedule an appointment with Yan Wang?
Apply for one of the trials that Yan Wang is conducting.
What is the office address of Yan Wang?
The office of Yan Wang is located at: Xiamen Cardiovascular Hospital Xiamen University, Xiamen, Fujian 361008 China. This is the address for their practice at the Xiamen Cardiovascular Hospital Xiamen University.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.